These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 34043031)
41. [Value of immunotherapy in the perioperative treatment of localized muscle invasive bladder cancer]. Lewerich J; Schmid SC; Gschwend JE; Retz M Urologie; 2023 Mar; 62(3):279-287. PubMed ID: 36449033 [TBL] [Abstract][Full Text] [Related]
42. Is there a role for maintenance therapy after platinum chemotherapy in bladder cancer in the era of immune therapy? Rassy E; Assi T; Kattan J Future Oncol; 2019 Dec; 15(34):3877-3879. PubMed ID: 31729240 [No Abstract] [Full Text] [Related]
43. Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer. Stühler V; Maas JM; Bochem J; da Costa IA; Todenhöfer T; Stenzl A; Bedke J World J Urol; 2019 Sep; 37(9):1773-1784. PubMed ID: 30374610 [TBL] [Abstract][Full Text] [Related]
44. Emerging drugs for urothelial (bladder) cancer. Cumberbatch K; He T; Thorogood Z; Gartrell BA Expert Opin Emerg Drugs; 2017 Jun; 22(2):149-164. PubMed ID: 28556678 [TBL] [Abstract][Full Text] [Related]
45. The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era. Liu ST; Hui G; Mathis C; Chamie K; Pantuck AJ; Drakaki A Clin Genitourin Cancer; 2018 Apr; 16(2):e269-e276. PubMed ID: 29199023 [TBL] [Abstract][Full Text] [Related]
46. From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma. Hussain SA; Birtle A; Crabb S; Huddart R; Small D; Summerhayes M; Jones R; Protheroe A Eur Urol Oncol; 2018 Dec; 1(6):486-500. PubMed ID: 31158093 [TBL] [Abstract][Full Text] [Related]
48. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Balar AV; Castellano D; O'Donnell PH; Grivas P; Vuky J; Powles T; Plimack ER; Hahn NM; de Wit R; Pang L; Savage MJ; Perini RF; Keefe SM; Bajorin D; Bellmunt J Lancet Oncol; 2017 Nov; 18(11):1483-1492. PubMed ID: 28967485 [TBL] [Abstract][Full Text] [Related]
49. Durvalumab for the treatment of urothelial carcinoma. Alsharedi M; Srivastava R; Elmsherghi N Drugs Today (Barc); 2017 Dec; 53(12):647-652. PubMed ID: 29517083 [TBL] [Abstract][Full Text] [Related]
50. Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays. Schwamborn K; Ammann JU; Knüchel R; Hartmann A; Baretton G; Lasitschka F; Schirmacher P; Braunschweig T; Tauber R; Erlmeier F; Hieke-Schulz S; Weichert W Virchows Arch; 2019 Nov; 475(5):599-608. PubMed ID: 31267201 [TBL] [Abstract][Full Text] [Related]
51. Urothelial carcinoma in situ response to cisplatin-based neoadjuvant chemotherapy, or lack thereof: Impact on patient selection for organ preservation in muscle-invasive disease? Tachibana I; Bandali E; Calaway AC; Krishnan N; Cheng L; Adra N; Kaimakliotis HZ Urol Oncol; 2020 Nov; 38(11):850.e1-850.e7. PubMed ID: 32693973 [TBL] [Abstract][Full Text] [Related]
52. Update on chemotherapy for advanced bladder cancer. Rosenberg JE; Carroll PR; Small EJ J Urol; 2005 Jul; 174(1):14-20. PubMed ID: 15947569 [TBL] [Abstract][Full Text] [Related]
53. Docetaxel for the treatment of bladder cancer. Albany C; Sonpavde G Expert Opin Investig Drugs; 2015; 24(12):1657-64. PubMed ID: 26535615 [TBL] [Abstract][Full Text] [Related]
54. Systemic chemotherapy in locally advanced and/or metastatic bladder cancer. Pectasides D; Pectasides M; Economopoulos T Cancer Treat Rev; 2006 Oct; 32(6):456-70. PubMed ID: 16935429 [TBL] [Abstract][Full Text] [Related]
55. Update on the Treatment of Metastatic Urothelial Carcinoma. Bukhari N; Al-Shamsi HO; Azam F ScientificWorldJournal; 2018; 2018():5682078. PubMed ID: 29977169 [TBL] [Abstract][Full Text] [Related]
56. Systemic therapy in muscle-invasive and metastatic bladder cancer: current trends and future promises. Aragon-Ching JB; Trump DL Future Oncol; 2016 Sep; 12(17):2049-58. PubMed ID: 27306417 [TBL] [Abstract][Full Text] [Related]
57. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment. Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403 [TBL] [Abstract][Full Text] [Related]
58. Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice. Grivas P; Agarwal N; Pal S; Kalebasty AR; Sridhar SS; Smith J; Devgan G; Sternberg CN; Bellmunt J Cancer Treat Rev; 2021 Jun; 97():102187. PubMed ID: 33839438 [TBL] [Abstract][Full Text] [Related]